KCM
FATE icon

Kennedy Capital Management’s Fate Therapeutics FATE Stock Holding History

Kennedy Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-104,881
Closed -$2.35M – 622
2022
Q3 		$2.35M Sell
104,881
-725
-0.7% -$20.9K 0.07% 391
2022
Q2 		$2.62M Sell
105,606
-1,194
-1% -$32.9K 0.07% 386
2022
Q1 		$4.14M Buy
106,800
+848
+0.8% +$32.8K 0.1% 347
2021
Q4 		$6.2M Sell
105,952
-21,158
-17% -$1.2M 0.13% 295
2021
Q3 		$7.53M Buy
127,110
+16,584
+15% +$1.3M 0.17% 224
2021
Q2 		$9.59M Buy
+110,526
New +$8.91M 0.21% 172
2020
Q2 		– Sell
-75,200
Closed -$1.67M – 679
2020
Q1 		$1.67M Buy
+75,200
New +$1.9M 0.06% 493

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Kennedy Capital Management's FATE Position: Q4 2022 in Review

Kennedy Capital Management sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 104,881 shares — an estimated $2.35M sold.

Kennedy Capital Management first reported a position in FATE in Q1 2020 and held it in 7 quarters. The position peaked at $9.59M in Q2 2021. 227 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

  • Kennedy Capital Management reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Kennedy Capital Management sold 104,881 Fate Therapeutics shares in Q4 2022, an estimated $2.35M.
  • Kennedy Capital Management first reported a position in Fate Therapeutics in Q1 2020 and held it in 7 quarters.
  • Kennedy Capital Management's Fate Therapeutics position peaked at $9.59M in Q2 2021.
  • 227 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on Kennedy Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.